PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Amgen hands back heart failure programme rights to Cytokinetics

Amgen has handed back the rights to two investigational heart failure programmes to Cytokinetics after one of the drugs failed to demonstrate impressive results in a phase III study.

Amgen has terminated its collaboration with Cytokinetics and notified the company of its intension to transition the development and commercialisation rights for omecamtiv mecarbil and AMG 594.

In the GALACTIC-HF trial, omecamtiv mecarbil hit the primary endpoint of reducing the risk of cardiovascular death or heart failure events compared to placebo in chronic heart failure with reduced ejection fraction (HFrEF) patients. However, the drug failed to hit the key secondary endpoint of reducing the time to cardiovascular death.

“Our commitment to cardiovascular disease remains steadfast, and we look forward to continuing to work closely with the cardiovascular community as we focus on advancing our innovative therapies, including our Lp(a) inhibitor olpasiran (AMG 890), which is currently in phase II,” said David Reese, executive vice president of research and development at Amgen.

“We are grateful to the investigators and patients who participated in GALACTIC-HF. Unfortunately, the results of GALACTIC-HF did not meet the high bar we had set for the programme,” he added.

Amgen is also handing back the rights to AMG 594, which is currently in phase I development for HFrEF and other types of heart failure.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026